Multiple ascending dose study with the new renin inhibitor VTP-27999: Nephrocentric consequences of too much renin inhibition

Hypertension

Volumn 63, Issue 5, 2014, Pages 942-950

  Balcarek, Joanna ^a   Pessôa, Bruno Sevá ^b   Bryson, Catherine ^a   Azizi, Michel ^c,d   Ménard, Joël ^c   Garrelds, Ingrid M ^b   McGeehan, Gerard ^a   Reeves, Richard A ^e   Griffith, Sue G ^f   Danser, A H Jan ^b   Gregg, Richard ^a  

^a Vitae Pharmaceuticals   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e RAR Consulting LLC   (United States)

^f ClinPharma Resources   (United States)

Author keywords

Aldosterone; Angiotensins; Blood pressure; Humans; Pharmacokinetics; Renin

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; PLACEBO; PRORENIN; RENIN; RENIN INHIBITOR; UNCLASSIFIED DRUG; VTP 27999;

ADULT; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSED BLOOD PRESSURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION; SODIUM URINE LEVEL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ALDOSTERONE; ANGIOTENSINS; BLOOD PRESSURE; HUMANS; PHARMACOKINETICS; RENIN;

ADOLESCENT; ADULT; ALDOSTERONE; AMIDES; ANGIOTENSIN II; BLOOD PRESSURE; CARBAMATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUMARATES; HEMODYNAMICS; HUMANS; KIDNEY; MALE; MIDDLE AGED; PIPERIDINES; RENIN; YOUNG ADULT;

EID: 84902266944     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02893     Document Type: Article

References (14)

1. Fisher ND, Danser AHJ, Nussberger J, Dole W.P., Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008; 117: 3199-3205.
2. Azizi M, Ménard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther. 2013; 27: 145-153.
3. Jia L, Simpson RD, Yuan J, et al Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility. ACS Med Chem Lett. 2011; 2: 747-751.
4. Krop M, Lu X, Verdonk K., Schalekamp MADH, van Gool JMG, McKeever BM, Gregg R, Danser AHJ. New renin inhibitor VTP-27999 alters renin immunoreactivity and does not unfold prorenin. Hypertension. 2013; 61: 1075-1082.
5. Vaidyanathan S, Jarugula V, Dieterich H.A., Howard D., Dole WP Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008; 47: 515-531. (Pubitemid 351969826)
6. Campbell DJ, Nussberger J, Stowasser M., Danser AHJ, Morganti A, Frandsen E., Ménard J. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem. 2009; 55: 867-877.
7. Krop M, Danser AHJ. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep. 2008; 10: 112-118.
8. Azizi M, Bissery A, Lamarre-Cliche M, Ménard J. Integrating drug phar-macokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004; 43: 785-790. (Pubitemid 38405588)
9. Lange S, Fraune C, Alenina N., Bader M, Danser AHJ, Frenay AR, van Goor H, Stahl R, Nguyen G, Schwedhelm E, Wenzel UO. Aliskiren accumulation in the kidney: no major role for binding to renin or prorenin. J Hypertens. 2013; 31: 713-719.
10. Feldman DL, Jin L, Xuan H., Contrepas A, Zhou Y, Webb R.L., Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Danser AHJ, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro) renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension. 2008; 52: 130-136.
11. Schalekamp MADH, Derkx FHM, Deinum J, Danser AHJ. Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors. J Hypertens. 2008; 26: 928-937. (Pubitemid 351520980)
12. Owen RA, Molon-Noblot S, Hubert M.F., Kindt MV, Keenan KP, Eydelloth RS The morphology of juxtaglomerular cell hyperplasia and hypertrophy in normotensive rats and monkeys given an angiotensin II receptor antagonist. Toxicol Pathol. 1995; 23: 606-619.
13. Sequeira López ML, Pentz ES, Nomasa T, Smithies O, Gomez RA. Renin cells are precursors for multiple cell types that switch to the renin pheno-type when homeostasis is threatened. Dev Cell. 2004; 6: 719-728. (Pubitemid 38579354)
14. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Am J Cardiol. 1987; 60: 179-184. (Pubitemid 17132122)